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INTRODUCTION  
 Coronary Heart Disease has been defined by WHO as ‘Impairment of 
heart function due to inadequate blood flow to the heart compared to its 
needs, cause by obstructive changes in coronary flow’. Coronary heart disease 
(45,46)
 contributed 15.3 million deaths in 2000, accounting for 30% of the 
global death toll that year. They accounted for 45.6% of all deaths in the 
developed countries and 24.5% of all deaths in the developing countries. In 
absolute numbers the developing countries contributed 9.77 million deaths 
due to CHD, in contrast to 5.52 million in developed countries (an excess of 
76%). 
 Apart from the excess absolute mortality the early age of CHD related 
deaths in the developing countries is also a cause for concern. In a large 
country like India, more than half of the CHD deaths (52.2%) occurred below 
70 years. Indians around the globe have the highest rates of morbidity and 
mortality from coronary artery disease (CAD), despite the fact that nearly half 
of them are lifelong vegetarians. CAD rates among Indians are 2 to 4-fold  
higher overall and 5 to 10-fold higher in those younger than 40 years of age, 
irrespective of gender, region, religion, or social class.  High level of 
lipoprotein (a) provides the nature of genetic susceptibility. Unhealthy life-
style associated with affluence, urbanization  and mechanization adds to the 
problem. During the past 30 years, CAD rates in most developed countries 
have declined by 30-60% as a result of population –wide reduction in risk 
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factors along with advances in the medical management. Reduction in risk 
factors explains more than half the decline. Ironically, the CAD rates doubled 
in India during the same period, primarily due to dietary changes associated 
with transition from a rural sustenance economy to an urban oriented 
economy. 
 Myocardial infarction accounts for 33% of the total mortality 
associated with coronary artery disease. Half of the victims die before 
reaching the hospital. Early recognition and prompt treatment significantly 
reduce the mortality and morbidity of Myocardial infarction. Atherosclerotic 
changes in the coronary arteries are the most important cause for Ischemic 
Heart Disease. There are certain well known risk factors for atherosclerosis 
as,  
 Family history, Hypertension, Diabetes Mellitus, Cigarette smoking, 
Low HDL concentration, Old age, Male gender, Hyperfibrinogenemia, 
Hyperhomocysteinemia, Physical inactivity, Obesity.  
 Diabetes mellitus has been proved to be a very strong risk factor for 
coronary heart disease. In the last decade, a series of longitudinal studies have 
shown that increased urinary albumin excretion below the level of clinical 
albuminuria, so called microalbuminuria strongly predicts development of 
nephropathy in Diabetes mellitus. Microalbuminuria defined as albumin 
excretion 20-200µ gm/mt or 30-300 mg /day in urine is considered a novel 
atherosclerotic marker. Microalbuminuria reflects a more generalized 
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pathological process of the vascular system affecting the glomeruli, retinal 
vessels, and the intimal larger vessels simultaneously. The association 
between microalbuminuria and peripheral markers of endothelial damage or 
dysfunction, such as Von Willebrand factor, and its association with 
lipoprotein (a), insulin resistance etc.  Suggests the possibility that 
microalbuminuria may be a simple cheap and easy index of endothelial 
abnormalities in cardiovascular disease.  
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AIMS AND OBJECTIVES 
1. To estimate the incidence of microalbuminuria in nondiabetic 
patients with at least one Myocardial Infarction in past 2 years. 
2. To determine whether microalbuminuria is an independent marker 
of Myocardial Infarction in nondiabetics.  
3. To correlate the incidence and severity of microalbuminuria with  
a. Detailed physical examination to detect any particular finding 
significantly correlating with microalbuminuria.  
b. Various hematological and biochemical parameters.  
c. Echo changes of systolic and diastolic dysfunction.  
 
 
 
 
 
                                                  
REVIEW OF LITERATURE 
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 The evidence for proteinuria in diabetic patients dates back to 18th 
century. In 1836 Bright postulated that albuminuria could reflect a serious 
renal disease specific to diabetes(7). In the 1930’s Kimmelstiel and Wilson 
described the characteristic pathological lesion of kidneys in long standing 
Diabetes(8).  During the last decade, several longitudinal studies have shown 
that increased urine  albumin excretion below the level of clinical albuminuria 
i.e. microalbuminuria strongly predicts development of  nephropathy in 
Diabetic population(10). Recent studies have shown association of 
microalbuminuria with diverse conditions like cardiovascular disease(1),(2),  
endothelial dysfunction(4), insulin resistance(11), systemic hypertension(12,13), 
coronary artery disease(14) and dyslipidemias(15). 
MICROALBUMINURIA – DEFINITION  
 The term microalbuminuria was coined in Guy’s hospital in London in 
1982(16). It has been defined as urinary albumin excretion 
 >30 mgm/24hr.(20µgm/mt) 
 ≤  300mgm/24hr. (200µgm/mt) 
 irrespective of how sample is collected.  
PATHOPHYSIOLOGY AND PATHOGENESIS  
 The glomerular – capillary blood urine barrier can be regarded 
functionally as a membrane perforated by pores of an average size of 5.5 nm 
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and with uniform charge. Passage of molecules across the glomerular 
basement  membrane depends on size and charge of particle and a set of 
metabolic  factors and hemodynamic factors acting on it. 
Metabolic factors – In diabetes, Advanced Glycated End products 
(AGE), polyol pathway, protein kinase C which all may induce tissue injury, 
lead to decreased charge selectivity  of glomerular basement membrane, loss 
of glomerular fixed  negative charges, extra cellular matrix cross linking and 
activation  of cytokines.  
Hemodynamic factors –Vasoactive  hormones like endothelin and 
angiotensin II, AGE, Glucose, TGF-β   all have been implicated among the 
hemodynamic factors causing albumin leakage.   
 Among  these, the change in charge selectivity  has support  in the 
studies made by Kofoed – Enevoldsen et al.(47) in 1996. The primary 
population in this  cross –sectional study was 124 subjects aged 40 to 75 years 
without glucose intolerance and with  a previous (3 years before the present 
study) urinary albumin excretion rate (UAE) in the normal (<20 
microgram/min) or microalbuminuric (>20 microgram/min) range. The 
secondary population consisted of 39 offspring aged 15 to 40 years. The main 
outcome measures included UAE, urinary IgG/lgG4 selectivity index (SI), 
and the presence of ischemic heart disease as determined by questionnaire or 
ECG. A significant inverse correlation was found between SI and UAE. The 
reduction in SI was found with increasing age, independent of UAE. In non 
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diabetic subjects the development of microalbuminuria is associated with 
reduced SI, suggesting impairment of glomerular charge selectivity.  
MICROALBUMINURIA & ATHEROSCLEROTIC DISEASES  
 Mongensen CE(17) in Denmark and Jarrett(18) et al in Britain were the 
first to explore the role of microalbuminuria as a marker of cardiovascular 
risk factors, in patients  with NIDDM.  
 The association between microalbuminuria and cardiovascular 
mortality is not confirmed to diabetic individuals only microalbuminuria 
predicts vascular disease in non-diabetic population makes it a more universal 
marker  of early death from cardiovascular disease in humans. Yudkin et al 
had shown as 24 fold increase in mortality since it has been recently shown to 
extend to general population by Winocour et al.(19) 
 Indeed the demonstration by Yudkin et al(1) that rate in people with 
microalbuminuria. This observation has been tried to be explained by Deekert  
et al in the Steno hypothesis in diabtologia 1989(20) as follows- 
‘Microalbuminuria is caused by loss of negative charge of glomerular 
basement membrane, permitting leakage. Similar changes occur in blood 
vessels that  allow  atherosclerotic  lipoproteins to enter vessel wall’. In other 
words, microalbuminuria  reflects a glomerular manifestation of an otherwise 
generalized vascular hyperpermeability state.  
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 Other workers have reported association of microalbuminuria with 
lipid abnormalities (increased Lp(a) & decreased HDL)(15). Stehouwer et al 
reported a high von Willebrand factor  in relation to urinary albumin excretion 
and cardiovascular disease. Coller et al(22) also noted high VWF levels and  
increased free radical  activity in NIDDM with microalbuminuria. Thus the 
onset of microalbuminuria signals  highly athrogenic milieu in both diabetics 
and nondiabetics. 
 The association of microalbuminuria and atherogenic risk factors was 
also studied in 1998 by Kim et al(48). They studied  cross-sectionally 497 
clinically  healthy non-diabetic subjects more than 40 years of age who lived 
in Korea for the prevalence of microalbuminuria and  various cardiovascular 
risk factors. Subjects with microalbuminuria had significantly  higher values 
in age, BMI, waist –hip-ratio in females, blood pressure, plasma cholesterol 
and   fasting plasma insulin. Multiple  logistic  regression analysis when 
applied showed these were independently associated  with  microalbuminuria.  
Jensen JS et al(49)  in 1995 also studied the association between 
microalbuminuria and atherosclerotic risk factors. They studied 40-65  years 
old clinically healthy subjects, all of them participants of Copenhagen city  
heart study and found that in the microalbuminuric group systolic and 
diastolic blood pressures were both elevated and serum apolipoprotein 
(apo)A-1 concentration  was lower, also  serum HDL cholesterol tended to be 
low, whereas body weight, BMI  and serum fasting insulin was  elevated. 
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They concluded that microalbuminuria in clinically  healthy subjects is 
associated with increased levels of atherogenic risk factors. 
 In the D.E.S.I.R study Mennen LI(50), et al studied  the relationship 
between microalbuminuria and tissue-type plasminogen activator antigen 
(tPA-ag)  and fibrinogen in non diabetic subjects. The results of this study 
suggest that in non-diabetic men, microalbuminuria is associated with 
fibrinogen, but with tP-A-ag only when concomitant with hypertension.  
MICROALBUMINURIA AND ESSENTIAL HYPETENSION  
 Prevalence of microalbuminuria in hypertension has been reported 
over  a wide range in studies all over the world. The level of albuminuria  is 
more closely associated with ambulatory blood pressure. The interaction 
between albumin excretion and BP is enhanced by obesity and smoking. 
Hypertensive with higher  Body Mass Index and high waist – hip ratio had 
high prevalence  of microalbuminuria which was shown by Bonnet J. et al 
2001, Donovan SJ 2000, Campese VM et al 2000. Although  the  true 
relevance of microalbuminuria as a marker of cardiovascular  risk or 
hypertensive renal damage needs to established, it appears  to be a significant 
risk factor.(24,31) 
 Microalbuminuria may be an  early indicator of target organ  damage 
namely, LVH, retinal vascular lesion, increased  carotid artery wall thickness 
and glomerular hyperfiltration. Microalbuminuria is also associated with 
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abnormal circadian  pattern  of blood pressure ie higher 24 hours mean level, 
Low day: night ratio ( non –dipper) and hyper variability of pressure 
readings.(23) Thus  in essential hypertension, microalbuminuria is a marker of 
the presence of high blood pressure throughout  24 hours period. West JN 
1991 and Gosbing P et al 1991; found a direct correlation between grading of 
microalbuminuria and staging of essential hypertension.  
 To identify biological co-variates of microalbuminuria in non-diabetic 
subjects, brachial BP, echocardiographic left ventricular mass and other 
cardiovascular and  metabolic parameters were evaluated  in 211 untreated 
males (38 normal controls, 109 uncomplicated stage 1 to 3 essential 
hypertensive and   64 patients with stable atherosclerotic peripheral vascular 
disease either with (n=44) or without (n-20) essential hypertension with 
normal cardiac and renal  function). Compared with nonalbuminurics, 
microalbuminurics had high systolic BP,comparable diastolic pressure and so 
high pulse pressure.  Greater prevalence of hypertension, peripheral vascular 
disease, LVH and decreased HDL cholesterol further distinguished 
microalbuminuria from non-albuminuria in univariable comparison. This 
association of microalbuminuria with wider pulse-pressure, a correlate of 
pulsatile hemodyamic load and conduit vessels stiffness as well as an 
important cardiovascular risk factors, may explain why microalbuminuria 
predicts cardiovascular events in non diabetic subjects.  
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 The association of microalbuminuria   with pulse pressure and isolated 
systolic hypertension was demonstrated by Cirillo M> et al in the GUBBIO 
study Collaborative Research Group.(25) The study shows the  relationship of 
pulse pressure and isolated systolic hypertension to microalbuminuria in non-
diabetic subjects. Overnight urinary albumin and creatinine excretion, fasting 
plasma glucose, cholesterol, weight, height, medical history and smoking 
habits were studied. It demonstrated that in non –diabetic middle aged adults, 
isolated   systolic hypertension and pulse pressure is directly related to 
microalbuminuria independent of diastolic pressure and other correlates.  
MICROALBUMINURIA AND ENDOTHELIAL DYSFUCTION 
 Yudkin JS et al had demonstrated in 1988 that microalbuminuria is a 
predictor of vascular disease in even non-diabetic subjects. The steno 
hypothesis in Diabetologia 1989 suggested microalbuminuria reflects a 
glomerular manifestation of an otherwise generalized vascular 
hyperpermeability state. The pathophysiology of increased transcapillary 
escape  rate of albumin (TER-alb) is unknown  but could be caused by 
hemodynamics or damage to  the functional properties of the  vascular wall. A 
number of studies has provided incidence of endothelial dysfunction in 
patients with microalbuminuria. In this context a number of markers of 
endothelial cell dysfunction have been found to be increased in patients with 
microalbuminuria.  
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 Microalbuminuria is considered a novel atherosclerotic risk factor. 
This is supported by two preliminary minor studies.  
- Copenhagen City Heart Study and  
- MONICA Population study. The aims of these were- 
1. To examine whether a relationship exists between 
microalbuminuria and atherosclerotic cardiovascular disease in the 
general  population. 
2. To illuminate possible pathophysiological mechanism underlying 
this association.  
In this 3rd  Copenhagen City Heart Study a cross sectional analysis 
comprising 2613  individuals without diabetes mellitus or renal / urinary tract 
disease revealed a positive  association between overnight urinary albumin 
excretion rate and a  history of acute myocardial infarction. This association 
was independent of age, sex, conventional atherosclerotic risk factors and 
GFR. Participants with albumin exertion rate exceeding upper value of 
(>7µg.ml) in the entire population had higher frequency of previous acute 
myocardial infarction than others.  
 In the 1st Monica Population study in Copenhagen , 2085 individual  
without diabetes, cardiovascular disease, renal / UTI were followed for 10 
years. Participants with high albumin/ creatinine ratio had a relative risk of 
2.3  for developing IHD. This was observed independent of age, sex and 
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conventional atherosclerotic risk factors. Measurement of glomerular 
filtration rate and tubular function made it unlikely that the difference  in 
urinary albumin between the two study groups was due to local renal 
conditions, although  reduction in both glomerular charge  selectivity and size 
selectivity were  observed in microalbuminuric individuals. Individuals with 
microalbuminuria had increased transvascular  albumin leakage to a level  
similar to that seen among  individual  with clinical atherosclerosis. This was 
not explainable  by difference in BP, lipoprotein levels, plasma volume, 
albumin concentration, anthropometry, insulin sensitivity  or smoking  habits. 
It is hypothesized that the  systemic transvascular leakiness may  also include 
lipoproteins, thus allowing for an increased  lipid transudation into the vessel 
walls. The leakiness might be due to hemodynamic factors of structural or 
functional perturbations of the endothelium. Further studies may demonstrate 
the exact nature of endothelial dysfunction.  
 Jensen JS  et al in 1995(51) at the Steno Diabetes Center in Denmark 
conducted a study to test the hypothesis that microalbuminuria in clinically 
healthy subjects is associated with a systemic transvascular  albumin 
leakiness. They found that the positive correlation between urinary albumin 
excretion rate on continuous scale   and the fractional disappearance rate of 
albumin from plasma compartment was independent of age, sex, smoking 
status, blood pressure, body size,  plasma volume, plasma albumin  
concentration  and concentrations of blood glucose,  serum  insulin and serum 
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lipids. In conclusion, microalbuminuria is an independent marker of systemic 
transvascular albumin leakiness in clinically healthy subjects.  
Garg JP et al(53) 2002 has also described microalbuminuria as a marker of 
vascular  dysfunction and risk factors for cardiovascular disease. They have 
described microalbuminuria as a signal from the kidney that cardiovascular 
risk is increased and the vascular responses are altered. They suggested that a 
reduction in the rise of microalbuminuria is a significant consideration in the 
selection of agents to treat a given risk factor (cholesterol or blood pressure) 
to a recommended target goal.  
Pedrinelli R, et al 2001(54) studied microalbuminuria in non diabetics 
and  observed that microalbuminuria might  be considered as an integrated 
marker of cardiovascular risk sensitive to systemic vascular status in addition 
to other parameters such as blood pressure levels, glucose metabolism, 
smoking habits, a profile  rather unique among the prognostic predictors 
available to stratify risk in hypertensive patients.  
MICROALBUMINURIA AND INSULIN RESISTANCE 
Reaven (1998) has proposed that insulin resistance/ hyperinsulinemia 
is the common denominator between conventional cardiovascular risk factors 
and development of atherosclerosis. Thus individual  risk factors such as 
hypertension, obesity, hyperlipidemia and glucose intolerance commonly 
contribute to form a clinical syndrome    characterized by underlying state of 
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insulin resistance and devastating cardiovascular outcome, which Reaven 
referred to a s syndrome X. There is now evidence to promote 
microalbuminuria as a distinct and independent facet of this disorder. 
 Niskanen L et al(28) proved the association of NIDDM with 
microalbuminuria, while Forsblom CM  et al in their  study in 1995(29) proved 
that microalbuminuria and insulin resistance existed in non-diabetic first 
degree relatives of people with NIDDM. The Insulin Resistance 
Atherosclerosis study (IRAS) 2000(30) studied the relationship of 
microalbuminuria with two well known markers of inflammation – CRP and 
Fibrinogen. Both were related with significant association after adjustment for 
demographic variables, diabetic status, smoking and use of ACE inhibitors. It 
showed association of CRP and fibrinogen with microalbuminuria in non –
diabetic individuals. 
MICROALBUMINURIA –CORRELATION WITH IHD AND 
ATHEROSCLEROTIC RISK FACTORS(31)  
 The association of microalbuminuria with vascular disease has been 
reported in diabetic and non-diabetic individuals. It has been suggested that 
microalbuminuria reflects a more generalized pathological process of the 
vascular system affecting the glomeruli, retinal vessels and the intimal larger 
vessels, simultaneously.  
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 Jensen JS et al in 1997 made a population based study of 1254 
hypertensive patients at Epidemiological Research Unit.(33) at the State  
University Hospital, Copenhagen. The aim of this study was a cross – 
sectional analysis to show whether microalbuminuria is related to a higher 
prevalence of cardiovascular disease, a more atherogenic risk profile and 
reversibly related   to the use of antihypertensive drugs. The study showed 
microalbuminurics to have higher age, systolic BP, male predominance as 
compared to others. It was concluded that slightly elevated albumin excretion 
in the urine is not only a pressure dependent functional phenomenon, but 
associated  with permanent atherosclerotic  damage in the entire  vascular  
system.  
 Taskiran M. et al in 1998(55) studied urinary albumin excretion in 
hospitalized patients with acute myocardial infarction at the Department of 
Cardiology, Copenhagen. The aim of this study was to measure the urinary 
albumin excretion in patients with acute myocardial infarction, and to 
correlate this with known atherosclerotic risk factors. 126 patients and 56 
healthy controls matched for age and sex were studied. The albumin 
/creatinine  concentration ratio in morning urine specimens was calculated  as 
an index of the albumin  excretion.  The frequency of microalbuminuria was 
higher in patients than controls. This difference was independent of blood 
pressure, body weight, smoking, diabetes mellitus, renal disease and 
thrombolytic treatment. There was a positive correlation between urinary 
albumin excretion and thickness of the left ventricle wall, which was 
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independent of blood pressure. Follow –up examination of the patients will 
reveal whether microalbuminuria increases the risk for recurrence of acute 
myocardial infarction.  
MICRO-HOPE STUDY 
 To describe the characteristics of diabetics and non-diabetics in the 
Heart Outcome Prevention Evaluation (HOPE) study who are at high risk to 
develop cardiovascular disease and who have microalbuminuria and to 
identify the key determinants of microalbuminuria in these two groups – 
MICRO- HOPE (34) (microalbuminuria, Cardiovascular and renal outcome) 
sub study  was done.  
 Albuminuria was measured in 97% of patients enrolled in HOPE study. 
Baseline clinical characteristics of diabetic and non-diabetic participants with 
microalbuminuria were   recorded and univariate and multivariate relationship 
between these characteristics and the presence of microalbuminuria was  
estimated for both groups. It was concluded that microalbuminuria is 
independently associated with several risk factors for cardiovascular and renal 
disease in both diabetic and non-diabetic at high risk for cardiovascular 
disease.  
PREVENDIT (35) 
  The American Journal of Cardiology describes the rationale, design 
and baseline characteristics of a trial to determine whether treatment with 
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fosinopril 20mg  in a day  and or pravastatin 40 mgm a day will prevent  
cardiovascular and renal disease in non-hypertensive (BP<160/100 mm Hg 
not on antihypertensives) and  nonhypercholesterolemics (Tch<8.0 mmol or 
<5.0 mmol in previous MI) not on lipid lowering drugs, men and  women 
with microalbuminuria. The PREVEND  IT. Studied 864 randomized subjects 
for  a minimum  of 4 years and maximum 5 years. The primary efficacy 
parameter was defined as the combined incidence of all cause mortality or 
hospital admission for documented-  
1. Nonfatal myocardial infarction 
2. Myocardial ischemia  
3. Heart failure  
4. Peripheral vascular  disease 
5. Cardiovascular disease  
6. End stage renal disease. 
Haffner SM et al has studied the relationship of microalbuminuria with 
cardiovascular disease in the San Antonio Heart Study(36) a population based 
study of 316 non-diabetic subjects. Microalbuminuria was significantly 
associated with higher blood pressure, triglyceride concentration, sum of 
insulin concentrations during a glucose tolerance test, and prevalence of 
hypertension and of self reported myocardial infarction. When subjects with 
hypertension were excluded, normotensives with microalbuminuria still had 
significantly higher triglyceride levels and serum insulin, suggesting that  in 
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increased atherogenic risk factor pattern exists even in  normotensive subjects  
with microalbuminuria.  
 Taskiran M(37)  et al have studied the incidence of urinary  albumin 
excretion in hospitalized patients with acute myocardial infarction. They have 
demonstrated a positive correlation between urinary albumin excretion and 
left ventricle wall thickness which was independent of blood pressure. The 
difference was independent of blood pressure, body weight, smoking, 
diabetes,  renal disease and thrombolytic treatment.  
 The Risk Factors Intervention study Group at Wallenberg Laboratory 
for Cardiovascular  Research, Sahlgrenska University Hospital, Goteborg 
University,  Sweden investigated the predictive value of microalbuminuria as 
a risk factor for true major cardiovascular events in non-diabetics with  treated 
hypertension. In a prospective  study over a period  of 3.3 years, overnight 
urinary  albumin was measured in 345 non  diabetics with treated 
hypertension, aged 50-72 years, either with serum cholesterol ≥ 6.5 m mol/L 
or smokers or both- This study proved microalbuminuria was associated with 
future major cardiovascular  events.  
Boehringer Mannheim GmbH, Germany tested the hypothesis that 
qualitative microalbuminuria screening  in a practice setting would  identify 
non-diabetic hypertensive  patients at high risk of developing cardiovascular 
disease. It studied 11.343 patients, of whom 25% had coronary artery disease, 
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17% had LVH, 5% had a stroke, 6% had peripheral vascular disease. Of these 
32% showed presence of microalbuminuria.  
MICROALBUMINURIA IN NON DIABETICS  
 Microalbuminuria in non diabetics was first described by Yudkin JS et 
al 1988(58) in the Islington Diabetes Survey. It was noted by logistic regression 
that diabetes, impaired glucose tolerance, systolic and diastolic blood 
pressures, smoking, age, sex, ethnic origin, and body mass index, were 
independently related to microalbuminuria and coronary heart disease even in 
non diabetics.  
 The Gubbio Population Study(56) done by Cirillo  M et al 1998 also  
studied microalbuminuria in nondiabetic adults in relation of blood pressure, 
body mass index, cholesterol levels and smoking. They tested the hypothesis 
that in nondiabetic middle –aged adults without macroalbuminuria, 
cardiovascular risk factors are related to urinary albumin excretion and 
prevalence of microalbuminuria. There were 1567 participants in the Gubbio  
population Study (677  men and 890 women) aged 45 to 64 years, without 
macroalbuminuria, without diabetes mellitus and with fasting plasma glucose 
levels less than 140 mg/dl. Data collection included albumin and creatinine 
excretion, level of fasting plasma cholesterol,  glucose, triglycerides, 
creatinine and uric  acid, creatinine clearance  red blood cell sodium- lithium 
counter transport; blood pressure, weight, height, medical history,  smoking 
status, and alcohol  intake. The conclusion of this study was that major  
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cardiovascular risk factors are independent correlates of microalbuminuria in 
non diabetic middle aged adults. Kim CH et al(48) also studied association of 
microalbuminuria and atherosclerotic risk factors in non-diabetic subjects.  
 Hillege HL, et al in 2001(57) described that microalbuminuria is 
common, also in a nondiabetic, nonhypertensive population, and is an 
independent indicator of cardiovascular risk factors and cardiovascular 
morbidity in the Journal Intern Med. The study was done to assess the 
prevalence of microalbuminuria in the general population especially in 
nondiabetic and nonhypertensive subjects, and its association with known 
cardiovascular risk factors and cardiovascular morbidity. In this cross 
sectional cohort study, cardiovascular risk factors and morbidity were 
validated in a well defined  nondiabetic and nonhypertensive group of 5241 
subjects. Microalbuminuria was present in 7.2% of the subjects and 
independently associated with age, gender, hypertension, diabetes, smoking, 
previous myocardial infarction and stroke. It concluded that microalbuminuria 
appears to be common not only in the general population but also in a 
nondiabetic, nonhypertensive   population and is independently associated 
with increased cardiovascular risk factors and cardio- vascular morbidity.      
MICROALBUMINURIA AND PERIPHERAL ARTERY DISEASE 
ASSOCIATION WITH CARDIOVASCULAR MORTALITY – HOORN 
STUDY.  
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 Microalbuminuria is associated with increased cardiovascular and all 
cause mortality. It has been proposed that microalbuminuria reflects 
generalized atherosclerosis and may thus predict mortality. To investigate this 
hypothesis, Hoorn study, studied the associations between, on one hand 
microalbuminuria  and peripheral artery disease, a generally accepted marker 
of generalized atherosclerosis and on the other hand, cardiovascular and all 
cause mortality in an age, sex and  glucose tolerance stratified sample (n=631) 
of a population cohort aged 50-75 followed preoperatively for 5 years. Both 
microalbuminuria and peripheral artery disease were associated with a 4-fold 
increase in cardiovascular mortality. After adjusting for age, sex, diabetes 
mellitus, hypertension, cholesterol levels, body mass index, smoking habits 
and previous IHD the relative risks were 3.2 for microalbuminuria and 2.4 for 
PAD. It concludes that both microalbuminuria and PAD are associated with 
an increased cardiovascular mortality. Microalbuminuria   and PAD are 
mutually independent risk factors. These data suggests that microalbuminuria   
affects mortality risk through a mechanism different from generalized 
atherosclerosis.  
MICROALBUMINURIA – IN THE ELDERLY 
  Studies over the past decade depict that incidence of microalbuminuria 
increases with age. Elderly hypertensives have higher prevalence of 
microalbuminuria than younger subjects(38) (Agarwall  et al 1995). 
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 Bone J et al 2001 showed that microalbuminuria positively correlated 
with age, systolic BP, body mass index waist to hip ratio, pulse pressure, 
decrease HDL cholesterol, increase triglycerides.  
 Agarwall B et al 1996(39) in the Journal Hypertension showed 
increased age correlates with microalbuminuria.  
 Reports of Copenhagen study group – Jensen J S et al(33) 1997 showed 
higher age to be associated with microalbuminuria.  
MICROALBUMINURIA – WITH HEIGHT AND SEX  
  Studies all over the world show a male preponderance in sex 
distribution of microalbuminuria. Regarding height, microalbuminuria is seen 
associated with short stature.  
 The Copenhagen study group(33) has shown association of  
microalbuminuria with short stature and male sex. Similar observations have 
also be made  by Gould MM et al, 1993. 
Male preponderance in microalbuminurics have also been shown by Mortin J 
et al 1996.(41) 
MICROALBUMINURIA – ETHNIC DIFFERENCES   
 In  NIDDM, prevalence of microalbuminuria has been shown to be 
7.6% in English and 42% in Norway population.(42) 
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 High rate and poor outcome is seen of diabetic nephropathy in 
nonwhite population than in whites. Summerson JH et al 1995 showed that 
black hypertensives had significantly higher urinary albumin excretion rates 
compared to whites.  
MICROALBUMINURIA AND OBESITY  
 Obese subjects have higher prevalence of microalbuminuria than non 
obese ones. This has been shown in subjects with hypertension in a number of 
studies of Bonet  J et al  2001, Donovan SJ  et all 200, Agarwall S et al 1993, 
MImran et al 1996.(24) The association of microalbuminuria  with body weight 
has  also been shown in patients  of acute myocardial infarction by Taskiran 
M> et al in 1998 .(58) In the Gubbio Population study 1998 Cirillio M et al(56) 
noted that microalbuminuria is associated with high BMI in non diabetics. 
Kim CH et al(48) in 1998 also had made similar observation.  
MICROALBUMINURIA AND SMOKING  
 Microalbuminuria is more prevalent in smokers than in non smokers.  
 Mimam et al 1997 (24) stated the higher prevalence – two fold higher of 
microalbuminuria in smokers as compared to non-smokers. Other studies like 
these of Jensen JS et al 1994,  Bigassi R et al 1999, Padrinelli Rs. 1997, 
Sprangles JG et al 1997 also showed  increased prevalence of 
microalbuminuria in smokers among the study population.  
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CORRELATION BETWEEN MICROALBUMINURIA AND 
CAROTID INTIMA, MEDIA THICKNESS 
 Bignazzi R et al43  1995 showed that the presence of microalbuminuria 
in subjects of hypertension was associated with increased thickness  of intima 
and media of the carotid arteries detected by ‘B’ mode ultrasound.  
 Pontremolli et al 199844 reported an increased intimal-medial carotid 
wall thickness (12.5±0.2mm) in microalbuminurics as compared to normal   
albuminurics (11.7±0.3mm). 
 Same observation has been made in Journal  Association of Physicians 
India (JAPI)  2002.14 
CORRELATION BETWEEN MICROLBUMINURIA AND SERUM 
URIC ACID  
Bigazze R et al13 1995 showed that high levels of uric acid was found 
in the serum of microalbuminurics as compared to normal albuminurics.  
 This has also been shown  by several other observers like  Bianchi S 
(1999), Congo-Mbenza ( 1999), Hirai A (2000), Ruilope LM (2001). 
CORRELATION  OF MICROALBUMINURIA AND SERUM 
HOMOCYSTEINE  
 Hoogeveen EK, et al in 199859 in the Hoorn Study  observed the 
relationship of microalbuminuria with serum homocysteine. They studied an 
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age, sex and glucose tolerance stratified random sample of 50 to 75 years old 
general Caucasian population (N=680). The urinary albumin to creatinine 
ratio was measure in an early morning spot urine sample. After adjusting for 
age, sex, glucose tolerance category, hypertension, dyslipidemia and smoking 
the odds ratio for total homocyteine increment was significant.They 
concluded that both hyperhomocysteinemia and protein  intake are related to 
microalbuminuria independent  of NIDDM and  hypertension. 
Hyperhomocysteinemia may partly explain the link between 
microalbuminuria and increase risk of cardiovascular  disease.  
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MATERIAL AND METHODS  
 The study was performed in Kilpauk Medical College, Chennai. Our 
idea was to perform a case control study. We decided to study 100 subjects, 
50 cases and 50 controls. Our cases were selected from Medicine wards, 
Cardiology and Medicine OPD and ICCU. We studied 50 patients with at 
least one Myocardial Infarction in past 2 years. Controls were all healthy 
subjects who were selected based on the  WHO (1969) definition of healthy 
subject, viz. 
1. They had no evidence of any disease or infirmity.  
2. They had a sense of physical, social and mental well being.  
3. They could perform their routine work without physical limitation.  
We matched these 50 Controls with the cases for age and they belonged to 
the same region as the cases with no overt symptoms of coronary artery 
disease and with a normal ECG. 
 The exclusion criteria were decided as follows.  
1. Age <30 and > 60 years 
2. Diabetes Mellitus  
3. Hypertension JNC Grade II or above.  
4. Congestive cardiac failure. 
5. Renal  Disease 
6. Gross Albuminuria 
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7. Females taking oral contraceptives. 
After the study population was designed we subjected them to a battery 
of investigations. Each individual was asked their history in details and 
subject to thorough clinical examination including General and System wise 
detailed  examination. Also were done the following tests. 
ECG, 
ECHO cardiograph,  
URINE albumin, sugar, ketone bodies.  
BLOOD for Hemoglobin, TLC, DLC, ESR, 
Urea, Creatinine,  
Fasting and Postmeal bloodsugar, 
 Uric acid, 
 S. cholesterol 
The methods for some of these tests are discussed in brief.     
MICRO ALBUMINURIA  
 In this study, we estimated the presence of albumin excretion by an 
immunoturbidimetric test.  
BASIS OF MICRAL TEST   
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 Micral test is an immunoassay specific for albumin. The test strip  
consists of a series of reagent pads. A chromatographic process, through the 
wick fleece to the buffer fleece, draws urine where the sample is adjusted to 
alkaline pH. In the conjugate fleece, albumin in the urine binds to a soluble 
conjugate of albumin antibody and beta galactosidase. Excess antibodies then 
bind to immobilized albumin in the capture matrix and then is effectively 
removed from the sample, so that the albumin bound to antibody enzyme 
complex reaches the color substrate pad. The substrate is chlorophenol red 
galactoside, which turns red when beta galactosidase splits galactose. The 
intensity of color produced is proportional to the albumin concentration in 
urine. The color found after 5 minutes is compared with a reference chart on 
the container. There are 3 color blocks reflecting albumin concentration of 
20,50, 100 mg/L. The Micral Test Strip has a sensitivity of 100% and 
specificity of 91%. 
TEST COMPONENT 
 One test strip contains monoclonal antibodies against human albumin 
(lgG) labeled with colloidal gold 6gm. and fixed albumin 9.5 mg.  
PROCEDURE   
1. Immerse the test strip into the urine such that the fluid level is just 
between the two black bars, withdraw the test strip after 5 seconds 
and place  it across the top of the urine vessels. While immersing 
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and withdrawing the test strip do not allow the test strip to touch  
the collection vessels.  
2. After 1 minute compare the color of test pad above the inscription 
“Micral” with the color scale on the test strip vial level. If the color 
development is slightly uneven average color is relevant. 
Comparison of the colour with the colour scale is possible for 
another 5 minutes then the colour disintegrates.  
DETECTION OF ALBUMIN CONCETRATION ABOVE 100 mg/24 
hrs.  
 The  urine sample in such cases can be diluted by mixing one part of 
urine with two parts of water, the original albumin concentration is then 
calculated by multiplying the result obtained by  three.  
SAMPLE MATERIAL  
 Albumin excretion is increased after physical activities. It is therefore 
recommended to use urine that has been produced at rest, that is first morning 
urine collected immediately after rising. The liquid intake must be in the 
normal range. If the urine analysis does not take place within 3 days, store the 
urine in refrigerator at temperature +2°c to +8°c. Urine that has been 
refrigerated (for max 2 week) must first be brought to at least +10°c. 
URINE  
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ALBUMIN  
 Albumin in urine was detected by heat precipitation test in the study. 
Make the urine slightly acid to litmus by, adding dilute acetic acid drop by 
drop, then filter or centrifuge to make urine clear. Test tube is filled three 
quarters with the urine and heat the top centimeter or two to boiling. Protein 
present is coagulated and seen by comparing with the unboiled  urine lower  
down the tube.  
 Acidification of urine is important, otherwise in alkaline urine large 
amount of urine protein after boiling remains uncoagulated and go 
undetected. Acidification is done with acetic acid (33 percent). It is a common 
practice to heat the clear urine before making it acidic. After boiling, add 
acetic acid even if precipitate appears or not. If precipitate is dissolved by 
adding acetic acid , it is phosphate,  if not then it is protein.  
SUGAR  
 Urine  sugar was detected by Benedict’s Quantitative test.  
 Reagent 1. Benedict’s Quantitative solution: 
 Dissolve 200 gms of sodium citrate, 75 gms of anhydrous sodium 
carbonate and  125 gms of potassium thiocyanate  in about 100 ml. of water. 
Pour this slowly, stirring continuously. Add 5 ml of 5 percent, potassium 
ferrocyanide solution and make  upto a litre with distilled  water.  
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 Reagent 2, Sodium carbonate (anhydrous) 
 Technique: Pipette 25 ml of the Benedict’s quantitative solution in to 
a 10 ml round bottomed  flask or beaker and  3 to 4 gms of sodium carbonate. 
Few pieces of porcelain are introduced to reduce bumping. Reagent is boiling 
urine ran slowly from a burette, shaking well at intervals. A white precipitate 
is formed and the blue color gradually disappears. End point is reached as the 
blue color completely disappears.   
Calculation: 0.05 gm of glucose reduced 25 ml of the alkaline copper 
solution. Hence: 
Grams  glucose per 100 ml urine 
   0.05x100xN 
                   =       -------------------- 
  ml required for the titration  
Where N= no. of times of urine was diluted.  
KETONE BODIES  
 Ketone  bodies in urine were detected by Nitroprusside (Rothera’s 
test). Saturate about 5 ml of urine with solid ammonium sulphate and add a 
little sodium nitroprusside, either about 0.5 ml of a percent  solution or a 
small quantity  of the powdered solid. Mix and add about 0.5 ml of 
concentrated ammonia. A purple  color is given by  acetoacetic acid  and 
acetone that is  maximal in about 15 minutes. If the  ammonia  is  layered on, 
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a simple ring is obtained at the junction of the liquids. The test  for ketone   
bodies is said to be positive.  
 
 
BLOOD GLUCOSE ESTIMATION  
METHOD : In this study we used GOD/POD method for estimation of 
fasting and postprandial blood sugar.  
PRINCIPLE : Glucose  is oxidized by the enzyme Glucose Oxidase (GOD)  
to give D-Gluconic acid  and hydrogen peroxide. Hydrogen peroxide in 
presence of enzyme  Peroxidase (POD) oxidizes phenol which combines with 
4 aminoantipyrine to produce  a red colored quinonimine dye. The intensity of 
the color developed is proportional to glucose concentration in the sample.  
     GOD 
 D-glucose +H2O+O2  --------------> D-gluconic acid +H2O2 
        POD 
 H2O2+ 4 Amonoantipyrine + Phenol -------------------> Red 
 Quinonimine dye +H2  
 
REAGENTS  
1. Enzyme reagent  
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2. Buffer solution  
3. Glucose standard 100 mg% 
 
NORMAL VALUES  
 Fasting  : 70-110 mg/dl – Normal 
   > 110-126 mg/dl- Impaired fasting glucose  
   > 126 mg/dl – diabetes mellitus  
After 2 hours of injection of 75 gms glucose.  
  <140mg/dl-Normal 
   140 -200 mg/dl- Impaired Glucose tolerance test  
  >200 mg/dl- diabetes mellitus  
SERUM CREATININE ESTIMATION  
 METHOD : In this study we used Jaffe’s  Alkaline Picrate method for  
estimation of serum creatinine. 
 PRINCIPLE:  In alkaline medium picric acid reacts with creatinine 
and produces  red coloured comples, whose absorbance is proportional to 
creatinine concentration. Non-creatinine chromogens are  also measured by 
this test which faslsely elevates the cretinine concentration. To over  come 
this sulphuric  acid is added., and non-creatinine chromogen remains 
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unaffected. This absorbance difference measured accurate creatinine 
concentration.  
 
REAGENTS  
1. Picric acid reagent.  
2. Sodium Hydroxide 2 N 
3. Standard 
NORMAL VALUE – 0.6 -1.2 mg/dl. 
BLOOD UREA ESTIMATION  
METHOD  : In this study, we used DAM method (Diacetyl  
Monoxime) for the estimation of Blood  urea nitrogen.  
 PRINCIPLES : Method is based on condensation of urea with DAM 
in an acidic medium. Urea reacts with  hot DAM in an acidic medium to 
produce coloured complex.  The color is intensified by using 
thiosemicarbazide and cadmium salt. The intensity of colour produced is 
proportional to urea concentration.  
REAGENTS  
1. Urea Reagent  
2. DAM (Diacetyl monoxime) 
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3. Urea standard  
EXPECTED VALUES 
 20-40mg% (10-20 mg urea nitrogen) 
ESTIMATION OF SERUM URIC ACID  
 METHOD : In this study, we used uricase method for quantitative 
estimation of uric acid in serum. 
PRINCIPLE  
 Uricase is a very specific enzyme acting on Uric Acid, end products 
being allantoin  and  hydrogen peroxide. Peroxidase is used to utilize 
hydrogen peroxide (proportional to uric acid concentration) to convert 
chromogens to coloured complex. The intensity of color produced is  
proportional to uric acid concentration and is measured  photometrically at 
546nm (530-570 nm or with green filter). 
    Uricase 
 Uric acid +O2+H2O ----------- allantion +CO2+H202  
H202 +4-aminoantipyrine      Perioxidase 
    +                ----------------------> Coloured complex  
 DCHBS 
 
REAGENTS  
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1. Uric acid (folic pack) 
  (Enzymes, chromogen) 
2. Uric acid (Buffer) 
3. Uric acid standard (6mg/dl) 
NORMAL VALUES  
 Serum uricacid  
 Male – 4-8 . 5 mg/dl;( 0.24 to 0.51 mmol/L) 
 Female – 2.7 to 7.3 mg/dl; (0.16 to 0.43 mmol/l) 
SERUM CHOLESTEROL 
 (One step method of Wybenga and Pileggi) 
PRINCIPLE  
 Cholesterol reacts with hot solution of ferric perchlorate, ethyl acetate 
and sulphuric acid (cholesterol reagent ) and gives a lavender coloured 
complex, which is measured colorimetrically.  
REAGENT  
 Reagent 1: Cholesterol reagent  
 Reagent 2: Working  Cholesterol standard,  200mg%.   
 Auxillary : Normal saline  
NORMAL VALUES  
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  Varies  with diet and age. Adult-150-250 mg./dl. 
OBSERVATION 
 
TABLE – 1 
INCIDENCE OF MICROALBUMINURIA IN CASES AND 
CONTROLS 
Microalbuminuria 
Positive Negative Total Population (N=100) 
Number Percentage Number Percentage 
Cases (n=50) 33 66% 17 34% 
Controls (N=50) 10 20% 40 80% 
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TABLE – 2 
DISTRIBUTION OF THE CASES ACCORDING TO AGE GROUPS 
AND IN RELATION TO MICROALBUMINURIA 
Microalbuminuria 
Positive Negative Age groups 
Male  Female Male Female 
30-35 (N=5) 1 - 4 - 
36-40 (N=5) 4 - - 1 
41-45 (N=8) 5 - 1 2 
46-50 (N=11) 7 1 - 3 
51-55 (N=13) 4 5 - 4 
56-50 (N=8) 4 2 - 2 
Total (N=50) (N=25) (N=8) (N=5) (N=12) 
Mean ± SD 48.76 ± 6.97   
The mean age group of microalbuminuria positive people among cases 
was 48.76 ± 6.97. 
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TABLE – 3 
DISTRIBUTION OF THE CONTROLS ACCORDING TO AGE 
GROUPS AND IN RELATION TO MICRO ALBUMINURIA 
Microalbuminuria 
Positive Negative Age groups 
Number Percentage Number Percentage 
30-35 (N=5) - - 5 - 
36-40 (N=5) - - 4 1 
41-45 (N=8) - - 6 2 
46-50 (N=11) 2 - 5 4 
51-55 (N=13) 3 - 1 9 
56-50 (N=8) 3 2 1 2 
Total (N=50) (N=8) (N=2) (N=22) (N=18) 
Mean ± SD 54.5 ± 4.12   
 
 The mean age group of microalbuminuria positive people among 
controls was 54.5 ± 4.12. 
 The mean age group difference noted among cases and controls 
showed that microalbuminuria was found in a lower age group (48.76 ± 6.97) 
in cases as compared to controls (54.5 ± 4.12). The difference was statistically 
significant. Z=3.22  P < 0.05. 
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TABLE 4 
DISTRIBUTION OF THE CASES ACCORDING TO SEX AND IN 
RELATION TO MICRO ALBUMINURIA 
Microalbuminuria 
Positive Negative Sex 
Number (%) Number (%) 
Males  N=30 25 (83.33%) 5 (16.66%) 
Females  N=20 8 (40%) 12 (60%) 
 Among cases males have higher incidence of microalbuminuria than 
females with statistical significance. χ2 = 10.04   P < 0.05. 
 
TABLE – 5 
DISTRIBUTION OF THE CONTROLS ACCORDING TO SEX AND 
IN RELATION TOM ICROALBUMINURIA 
Microalbuminuria 
Positive Negative Sex 
Number (%) Number (%) 
Males  N=30 8 (36.36%) 22 (73.33%) 
Females  N=20 2 (10%) 18 (90%) 
 Among controls males have higher incidence of microalbuminuria than 
females but without statistical significance. χ2 = 2.08  P > 0.05.  
TABLE – 6 
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DISTRIBUTION OF THE CASES ACCORDING TO SMOKING 
STATUS AND IN RELATION TO MIROALBUMINURIA 
Microalbuminuria 
Positive Negative Smoking Status  
Number (%) Number (%) 
Yes N=25 23 (92%) 2 (8%) 
No N=25 10 (40%) 15 (60%) 
 Among cases smokers had higher incidence of microalbuminuria than 
non smokers. χ2 = 15.06 P < 0.001 
TABLE – 7 
DISTRIBUTION OF THE CONTROLS ACCORDING TO SMOKING 
STATUS AND IN RELATION TO MICRO ALBUMINURIA 
Microalbuminuria 
Positive Negative Smoking Status  
Number (%) Number (%) 
Yes  N=18 8 (44.4%) 10 (55.5%) 
No  N=32 2 (6.25%) 30 (93.75%) 
 Among controls also smokers had higher incidence of 
microalbuminuria than non smokers. χ2 = 10.05  P < 0.05. 
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TABLE – 8 
DISTRIBUTION OF THE CASES ACCORDING TO BODY MASS 
INDEX AND IN RELATION TO MICRO ALBUMINURIA 
Microalbuminuria 
Positive Negative Body Mass Index 
Number (%) Number (%) 
> 25 21 (80.76%) 5 (19.24%) 
≤ 25 12 (50%) 12 (50%) 
 Among cases BMI > 25 was significantly associated with 
microalbuminuria with χ2 = 5.27  P < 0.05. 
 
TABLE – 9 
DISTRIBUTION OF THE CONTROLS ACCORDING TO BODY 
MASS INDEX AND IN RELATION TO MICROALBUMINURIA 
Microalbuminuria 
Positive Negative Body mass index  
Number (%) Number (%) 
> 25 5 (50%) 5 (50%) 
≤ 25 5 (12.5%) 35 (87.5%) 
 Among controls also microalbuminuria was significantly associated 
with BMI > 25. χ2 = 7.03   P < 0.05.  
TABLE – 10 
DISTRIBUTION OF THE CASES ACCORDING TO TOTAL 
CHOLESTEROL AND IN RELATION TO MICROALBUMINURIA 
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Microalbuminuria 
Positive Negative Total cholesterol 
Number (%) Number (%) 
> 200 22 (88%) 3 (12%) 
≤ 200 11 (44%) 14 (56%) 
 Among cases Total Cholesterol > 200 was observed to correlate 
significantly with microalbuminuria χ2 = 10.78  P < 0.001. 
 
 
TABLE – 11 
DISTRIBUTION OF THE CONTROLS ACCORDING TO TOTAL 
CHOLESTEROL AND IN RELATION TO MICROALBUMINURIA 
Microalbuminuria 
Positive Negative Total Cholesterol 
Number (%) Number (%) 
> 200 2 (33.33%) 4 (66.67%) 
≤ 200 8 (18.18%) 36 (81.81%) 
 But among controls Total Cholesterol > 200 did not correlate 
significantly with microalbuminuria χ2 = 0.76  P > 0.05. 
TABLE – 12 
DISTRIBUTION OF THE SMOKERS IN THE STUDY GROUP 
ACCORDING TO MICROALBUMINURIA 
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Positive Negative 
Microalbuminuria 
Number (%) Number (%) 
Positive (N=31) 23 (74.19%) 8 (25.80%) 
Negative (N=12) 2 (16.66%) 10 (83.33%) 
 
 Total smokers  = 43 
 Cases   = 25 
 Controls  = 18 
 Microalbuminuria positive people were more among cases than 
controls when the smokers of the study group were considered together. This 
was significant statistically also, 
 χ2 = 11.76 
 P < 0.05. 
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TABLE – 13 
ASSOCIATION OF BMI > 25 WITH MICROALBUMINURIA 
Positive Negative 
Microalbuminuria 
Number (%) Number (%) 
Positive (N=26) 21 (80.76%) 5 (19.23%) 
Negative (N=10) 5 (50%) 5 (50%) 
 
 Total smokers  = 36 
 Cases   = 26 
 Controls  = 10 
In the group with BMI > 25, Microalbuminuria positivity was seen 
more among cases than among controls. But χ2 = 3.41 P >0.05 makes it 
statistically insignificant. The 95% confidence Interval here has an upper limit 
26.58 and lower limit 0.65.   
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TABLE – 14 
ASSOCIATION OF TOTAL CHOLESTEROL > 200 
WITH MICROALBUMINURIA 
Positive Negative 
Microalbuminuria 
Number (%) Number (%) 
Positive (N=24) 22 (19.66%) 2 (8.33%) 
Negative (N=7) 3 (42.85%) 4 (57.15%) 
 
 Total smokers  = 31 
 Cases   = 25 
 Controls  = 6 
Microalbuminuria was seen more in cases than controls. 
 χ2  =  8.27  
 P < 0.001. 
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TABLE – 15 
ASSOCIATION OF MICROALBUMINURIA WITH SEX, SMOKING 
STATUS, BMI, TOTAL CHOLESTEROL  IN THE STUDY GROUP 
CASES (N=50) Microalbuminuria CONTROLS (N=50) 
Microalbuminuria 
 
Positive Negative Positive Negative 
Male 25 5 8 22 
Female 8 12 2 18 
Smoker 23 2 8 10 
BMI > 25 21 5 5 5 
Total 
cholesterol 
> 200 
22 3 2 4 
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DISCUSSION 
ASSOCIATION OF MICROALBUMINURIA WITH MYOCARDIAL 
INFARCTION 
 Out of the 50 cases present in this study microalbuminuria was found 
among 33, which was 66% while in controls this was only 10, which means 
20%. This difference among cases and controls was significant statistically 
too, X2 = 21.58  P < 0.001. This observation shows that microalbuminuria is 
associated significantly with Ischemic Heart Disease. The association of 
microalbuminuria with myocardial infarction has also been noted by Taskiran 
M et al.(55) in 1998. 
CORRELATION BETWEEN MICROALBUMINURIA & AGE 
 The age group of the subjects in this study was ≥ 30 and ≤ 60. Among 
cases microalbuminuria was found in different age groups as shown in tables 
No.2 and 3, it is seen that the mean age group of microalbuminuria positive 
cases was 48.76 ± 6.97 and that for controls was 54.5 ≤ 4.12. This clearly 
shows that microalbuminuria is seen at a younger age group among cases and 
the difference is significant Z = 3.22  P < 0.05. The observation of presence of 
microalbuminuria at higher age group among controls goes along with 
different studies done by Bonet J et al.2001, Agarwal39 B et al. 1996, Jensen 
JS et al. 33 1997 which showed that microalbuminuria is associated with older 
age group.  
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CORRELATION OF MICROALBUMINURIA WITH SEX 
 We had 60 males (30 cases, 30 controls) and 40 females (20 cases, 20 
controls) in the study group. As shown in Table No.4, among the cases 25 out 
of the 30 males had microalbuminuria while only 8 out of the 20 females had 
it. This shows that among cases males had higher incidence of 
microalbuminuria X2 = 10.04  
P < 0.05. 
 As per the Table No.5, among the controls only 8 out of 30 males had 
microalbuminuria and only 2 out of 20 females had the same. Even through 
males have a higher rate of microalbuminuria among controls the value is not 
statistically significant X2 = 2.08   P>0.05. If we consider cases and controls 
together males are having more incidence of microalbuminuria with statistical 
significance X2 = 8.81 P < 0.05. This observation is similar to the studies 
done by Gould MM et al., 1993, Mortin J et al. in 199641 and the Copenhagen 
study33 that microalbuminuria is associated with male sex. 
 
CORRELATION OF MICROALBUMINURIA WITH SMOKING 
 As evident from Table No.6, there were 25 smokers among the 50 
cases, all being males. Among these 23 (92%) had microalbuminuria which 
was significant χ2 = 15.06  P < 0.001. Which shows that microalbuminuria is 
significantly associated with smokers with MI. We also had 18 smokers 
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among the controls of which 8 (44.4%) had microalbuminuria as shown in 
Table no.7. This shows that majority of the controls who showed 
microalbuminuria were smokers (8 out of 10). 
 We took the smokers in the study group together and found that (Table 
No.12) of the 43 smokers 25(58.13%) were cases and 18 (41.86%) were 
controls. This shows the increased risk of IHD among smokers. We also 
noticed that among smokers 31 were having microalbuminuria. Of the 31,  
majority 23 (74.19%) belonged to cases and 8 (25.80%) controls. This 
observation that among smokers microalbuminuria positivity was seen more 
among cases with statistical significance (χ2 = 11.76 p < 0.001) makes it 
obvious that microalbuminuria can be considered independent of smoking 
status for risk of IHD. This observation is similar to those made by Mimarn et 
al. 1997(24), Jensen et al.(49), Pedrinelli et al. (54). 
CORRELATION OF MICROALBUMINURIA WITH BODY MASS 
INDEX 
 We classified the study group according to BMI > 25 or BMI ≤ 25. We 
found that among cases there were 26 with BMI > 25 as shown in Table No.8. 
Among these, microalbuminuria was seen in 21(80.76%) and  5 (19.24%) did 
not have it. This when analyzed was significant χ2 = 5.27  P < 0.05. This 
observation has gone along with those made by Bonet J et al. 2001, Donovan 
SJ et al 2000, Agarwall S et al. 1993, Mimran et al. 199624 that 
microalbuminuria is associated with high body mass index. When we 
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calculated the mean BMI for cases and controls we found that it was 24.16 ± 
2.559 and 23.χ 6.68 Respectively. This difference between the BMI of cases 
and controls was not significant statistically.  
 We also observed as in Table No.9 that microalbuminuria was seen in 
5 out of 10 controls who had BMI > 25 this was also significant statistically 
χ2 = 7.03 P < 0.05. This again shows association of microalbuminuria with 
high BMI.  
 As shown in Table No.13 we found that there were 36 people with 
BMI > 25 in the study group of this 26 (72.22%) were cases and 10 (27.77%) 
controls. This shown increased incidence of IHD in BMI > 25. We also 
observed that microalbuminuria was seen in 26 in the group, of which 21 
were cases and 5 controls. This showed that microalbuminuria was seen more 
among the cases with BMI > 25 than among the controls with BMI > 25. But 
this when analyzed was not significant statistically χ2 = 3.41 P > 0.05. Since 
the χ2 value is close to significant we apply the 95% confidence interval here. 
The 95% Cl in this cases has an upper limit 26.58 and a lower limit 0.65. It 
can be said that the chance of microalbuminuria positivity is more among 
cases at the high 26.58% and at the low 0.65% than the controls inspite of all 
having BMI > 25. This may show microalbuminuria to be an independent 
factor of IHD.  
CORRELATION OF MICROALBUMINURIA WITH TOTAL 
CHOLESTEROL 
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 We classified the study group according to total cholesterol > 200 and 
≤ 200. As per the Table No.10 there were 25 cases with total cholesterol > 
200, of these 22 (88%) were having microalbuminuria this was significant 
statistically also χ2 = 10.78 P < 0.001. We also had 6 controls as shown in 
Table no.11 with total cholesterol > 200, but only 2 (33.33%) of them had 
microalbuminuria, this was not significant χ2 = 0.76 P > 0.05. The association 
of microalbuminuria with lipid abnormalities has been reported by various 
research workers like Kim CH et al. (48). Jensen JS (49) Mennen LI et al.(50) and 
also. The mean value of total cholesterol of cases was 188.54 ± 29.25 and for 
controls was 174 ±  17.90 the difference being significant statistically.  
As seen in Table No.14 we grouped all the individuals with total 
cholesterol > 200 and found that there were 31 in total among those 25 
(80.64%) were cases and 6 (19.36%) were controls. This shows the 
association of increased total cholesterol with IHD. We also observed that in 
this group microalbuminuria was seen in 24. Of this 22 (91.66%) belonged to 
cases and 2 (8.33) belong to controls this was statistically significant χ2 = 
8.27 P < 0.001. This shows inspite of all having total cholesterol > 200, 
microalbuminuria was seen significantly among cases making it an 
independent marker.  
MICROALBUMINURIA IN CONTROLS 
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 In our study we observed that 10 persons out of 50 among the controls 
(20%) had microalbuminuria. Of these – 
 8 were males 
 2 were females 
 8 were smokers (all males) 
 5 had BMI> 25 
 2 had Total cholesterol > 200 
This shows that the finding of microalbuminuria among controls could be 
explained by all the 8 males being smokers and the 2 females being of older 
age group (60 year old).This observation is similar to those made by Jensen 
JS et al. 1995(49). Hillege et al. 2001(57). This also warrants the need for follow 
up of these individuals further.  
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SUMMARY 
 In the present study we took 100 individuals, of these 50 were cases all 
of them had at least one myocardial infarction in last 2 years. We had 29 cases 
of Anterior wall MI, 19 cases of Inferior wall MI, 2 had both. Of the IWMI 2 
had posterior wall involvement and 2 had right ventricle involvement. The 
other 50 were controls who were selected according to the WHO criteria for a 
healthy person. These individuals were investigated thoroughly in Kilpauk 
Medical College and Hospital, Chennai. Findings of the current study are as 
follows : 
1. Microalbuminuria is associated with IHD. In our study out of the 
50 cases 60% (N=33) had microalbuminuria while out of the 
controls only 20% (n=10) had microalbuminuria. 
2. Microalbuminuria was seen at a younger age group (48.76 ± 4.12). 
3. Male sex is associated with microalbuminuria. Among the 30 males 
in cases 25 (83.33%) had microalbuminuria.  
While among the 20 female cases only 8 (40%) had 
microalbuminuria.  
Among the 10 controls who had microalbuminuria 80% (n=8) were 
males.  
4. Smoking status is associated with increased risk of IHD. 
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We had 50 cases of which 50%  (n=25) were smokers. In our 
control group of 50, there were 36% (n=18) smokers.  
5. Microalbuminuria is seen more among smokers.  
In cases who are smokers (n=25), microalbuminuria was present in 
92% (n=23).In controls who are smokers (n=18) microalbuminuria 
was present in 44.4% (n=8). 
6. Microalbuminuria is independently associated with IHD, 
irrespective of smoking.  
Out of the 43 smokers, 31 had microalbuminuria. Among these 
majority 74.19% (n=23) were cases and only 25.80% (n=8) were 
controls.  
7. Higher BMI carries risk for IHD. In this study the BMI for cases 
was higher (24.16 ± 2.559) than that of controls (23 ± 6.68). Also 
of the total 36 with BMI more than 25 there were 26 cases.  
8. Microalbuminuria is associated with high BMI. 
In cases, 26 had a BMI > 25 of these 80.76% (n=21) had 
microalbuminuria while in controls, 10 had a BMI > 25 of these 
50% (n=5) had microalbuminuria.  
9. Microalbuminuria is associated with IHD irrespective of BMI. 
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We had 36 people with BMI > 25 of these 72.22% (n=26) fall 
among cases and only 27.77% 9n=10) were controls. There were 26 
people with microalbuminuria and BMI > 25. Of these 80.76% 
(n=21) were among cases and only 19.23% (n=5) among controls. 
10. High total cholesterol is a risk factor for IHD.  
In the present study the total cholesterol value was 188.54 ± 29.25 
in cases and was 174 ± 17.90 for controls.  
11. Microalbuminuria is associated with high cholesterol in IHD. 
Among cases there were 25 with total cholesterol > 200 of this 88% 
(n=22) had microalbuminuria. Among controls 6 had total 
cholesterol > 200 but only 33.33% (n=2) had microalbuminuria.  
12. Microalbuminuria is seen independently in IHD irrespective of total 
cholesterol.  
We had 31 people with total cholesterol > 200. We found that 24 of 
these had microalbuminuria. Of these 91.66% (n=22) were cases 
and only 8.33% (n=2) were controls. 
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CONCLUSION 
 The conclusions draw from the present study are as follows : 
1. The incidence of microalbuminuria in nondiabetic Myocardial 
infarction was 66%. 
2. Microalbuminuria is seen at a younger age group in MI. 
3. Microalbuminuria is associated with male sex significantly.  
4. Microalbuminuria is strongly associated with smoking. 
5. Smoking carriers a high risk for IHD. 
6. High Body Mass Index is associated with MI. 
7. Microalbuminuria is strongly associated with high Body Mass 
Index.  
8. Total cholesterol is significantly higher in MI. 
9. Microalbuminuria is strongly associated with high total cholesterol. 
10. Microalbuminuria is seen independent of smoking status, BMI, 
total cholesterol in patients of MI. 
11. Microalbuminuria is seen in older age groups and among smokers 
in normal subjects. 
 
BIBLIOGRAPHY 
1. Yudkin JS, Forrest RD, and Jackson C. Microalbuminuria as a 
predictor of vascular disease in non diabetic subjects. Lancet 1988. 
11 : 530-33. 
2. Microalbuminuria is independently associated with ischemic 
electrocardiographic abnormalities in large non-diabetic population. 
PREVEND (Prevention of Renal and Vascular Endstage Disease) 
TRIAL. European Heart Journal 2000, 21 : 1922-27. 
3. Gerstein HC, Mann JF, Pongue J, Yusuf S. Prevalence and 
determinants of microalbuminuria in high risk diabetic and non 
diabetic patients in HOPE study. Diabetes Care 2000 April, 23 : 35-
39. Suppl B. 
4. Felat – Rasmussen B, Nephrological Department, Rigs Hospital, 
Copenhagen, Denmark. Microalbuminuria, endothelial dysfunction 
and cardiovascular risk. Diabetes M etab 2000 July, 26 Suppl. 4 : 
64-6. 
5. Gosling P. Microalbuminuria a marker of systemic disease. British 
Journal of Hospital medicine, 1995, 54 : 285-90. 
6. Damsgaard EM, Froland A, Jorgensen OD, Mongensen CE, 
Microalbuminuria as a predictor of increased mortality in elderly 
people. British Medical Journal 1990, 300 : 297-300. 
7. Bright R. Cases and Observation illustrative of renal disease 
accompanied with the secretion of albuminous urine. Guy’s 
Hosptial Report, 1836 : 10-338-400. 
8. Kimmelsteil P, Wilson C. Intercapillary lesions in the glomeruli in 
the kidney. AM J Pathology, 1936, 12 : 83-97. 
9. Stehouwer CD, Naceta JJ, Zeldeurest GC, Donker AJ, Ottolander 
GJ, Urinary albumin excretion, cardiovascular disease and 
endothelial dysfunction in NIDDM. Lancet 1992, 3 : 340 : 319-23. 
10. Mongenson CE, Christensed CK. Predicting diabetic nephropathy 
in IDDM. New England Journal of Medicine, 1984-311 : 89. 
11. Yip J. Mattok MB, Morocutti A, Sethi M, Treviasa R. Insulin 
REsistance in IDDM with microalbuminuria. Lancet 1993, 342, 
883-87. 
12. Mimarn A, Microalbuminuria in essential hypertension. Clini Exp 
Hypertension 1997, 19 : 753-67. 
13. Bigazzi R, Bianchi S. Microalbuminuria as a marker of 
cardiovascular and renal disease in essential hypertension 
Nephrology Dialysis Transplant 1995, 10 (suppl 6) : 10-14. 
14. Microalbuminuria is associated with carotid intimal medial 
thickening and coronary Artery disease in Diabetics, JAPI 2002, 50 
: 1124-1129. 
15. Cummings MH,Watts GF, Tavakolian A, Fitzgerald A. Prevalence 
of micro albuminuria, lipoprotein(a), and coronary artery disease in 
the lipid clinic. Journal Clinic Pathology 1996 Jan, 49(1) : 19-23. 
16. Viberti GC, Mackintosh D, Bilous RW, Keen H. Proteinuria in 
diabetes mellitus, role of spontaneous and experiemental variation. 
Kidney 1982; 21 : 714-20. 
17. Mongensen CE, Microalbuminuria predicts clinical proteinuria and 
early mortality in maturity onset diabetes. NEJM 310 : 356-360, 
1984. 
18. Jarrett RJ, Viberti GC, Mahmud U. Microalbuminuria predicts 
mortality in NIDDM. Diabetic Med. 1984; 1 : 17-19. 
19. Winocour PH, Harland JOE, Miller JP, Laker MF : 
Microalbuminuria and associated cardiovascular risk factors in the 
community.Atherosclerois 1992 : 93 : 71-81. 
20. Deekert T, Feldt : Rasmussen B, Bore Johnsen K. Jensen T, Kofoed 
Enevolsen A : Microalbuminuria reflects widespread vascular 
damage. The Steno Hypothesis in Diabetalogia 1989; 32 : 219-226. 
21. Stehouwer CDA, Nauta JJP, Zeldenhurst GC : Urinary albumin, 
cardiovascular disease and endothelial dysfunction. Lancet 1992; 
340 : 329-323. 
22. Coller A, Rumley AG, Leach JP, Lowc GDO, Small M : Free 
radical activity and hemostatic factors in NIDDM patients with and 
without Microalbuminuria. Diabetes 1992; 41 : 909-13. 
23. Redon J et al : Ambulatory blood pressure and MAL in essential 
hypertension. J. Hypertension 1994 Aug 12 (8) : 947-53. 
24. Mimarm A ; Miicroalbuminuria in essential hypertension. Clin. 
Exp. Hypertension 1997; 19 : 753-67. 
25. Cirillo M, Stellato D, Laurnzi M. Panarrelli W, Zanchetti A, De 
Santo NG : Pulse pressure and isolated systolic hypertension : 
Association with microalbuminuria. The GUBBIO study 
Collaboration Research Group. Kidney Int. 2000 Sep :  58 (5) : 
1211-8. 
26. Jensen JS. Microalbuminuria and the risk of atherosclerosis clinical 
epidemiological and physiological investigations. Dan Med. Bull. 
2000 April, 47 (2) : 63-78. 
27. Reaven GM : Role of insulin resistance in human disease – diabetes 
1988 ; 37 : 1495-1507. 
28. Niskansen L, Laakso M : Insulin resistance is related to 
albuminuria with type-II diabetes mellitus. Metabolism 1993; 42 : 
1541-1545. 
29. Forsblom CM, Encksson JG, Teppo AM, Group LC, Ekstrand  VA 
: Insulin resistance and abnormal albumin excretion in non-diabetic 
first degree relatives of patients with NIDDM Diabetologia 1995; 
36 : 363-369. 
30. Festa A, D’Agortino R, Howard G, Mykkanen L, Haffner SM : 
Inflammation and Microalbuminuria in non-diabetic and NIDDM 
subjects : The Insulin Resistance Atherosclerosis Study Kidney Int. 
2000 Oct. 9 : 58(4) 1703-1710. 
31. Jensen JS, Foldt – Rasmussen B, Strandgard S, Schroll M, Borch 
Johnsen : Arterial Hypertension, Microalbuminuria and risk of 
IHD. Hypertension 2000 April; 35 (4) : 898-903. 
32. Lisowska – Myjak B : Microalbuminuria as a prognostic marker of 
cardiovascular diseases. Article in Polish Pol Merkuriusz Lek 1997  
July (13) : 28-29. 
33. Jensen JS, Feldt – Rasmussen B, Borch Johnson K, Clausen P, : 
Microalbuminuria and its relation to cardiovascular disease and risk 
factors : A population based study of 1254 hypertensive 
individuals. J. Hum Hypertension 1997, Nov. 11 : 727-32. 
34. Prevalence and determinants of microalbuminuria in high-risk 
diabetic and non-diabetic patients in the HOPE study.Gerstein HC, 
Mann JF, Pogue J. Dinnen SF, Halle JP, Joyce C, Voung J. Mc 
Master University, Mailton, Ontario, Canada Gerstein @ fhs. 
csu.mcmaster.ca. 
35. Diercks GF, Janseen WM, Von Boven AJ, Bak AA, De Jong PE, 
Van Gilst WH. Rationale, design and baseline characteristics of a 
trial of prevention of cardiovascular and renal disease with 
fosinopril and pravastatin in non-hypertensive, non-
hypercholestrolemic subjects with microalbuminuria (The 
Prevention of Renal and Vascular Endstage Intervention Trial) Am. 
J. Cardiology 2000 Sept. 15; 86(6) : 635-638. 
36. Microalbuminuria potential marker for increased cardiovascular 
risk factors in non-diabetic subjects? Haffner SM, Stern MP, 
Gruber MK, Hazuda HP, Mitchell BD. Department of Medicine, 
Unviersity of Texas Health Science Centre, San Antonio, 78284. 
37. Taskiran M, Rasmussen B,Jensen GB, Jensen JS : Urinary albumin 
excretion in hospitalized patients with myocardial infarction. 
Prevalence of microalbuminuria and correlation to left ventricle 
wall thickness. Scandinavian cardio vascular Journal 1998 : 32(3) : 
163-6. 
38. Agarwal S, Wikstrand J. Ljungman S, Herlitz H, Fagarberg B : 
Does microalbuminuria predict cardiovascular events in non-
diabetic men with hypertension. : The Risk Factor Intervention 
Study Group. Am. J. Hypertension 1995 April : 8, 337-42. 
39. Agarwal B, Berger A, Wolf K. Luft FC : Microalbuminuria 
screening by reagent strip predicts cardiovascular risk in 
hypertension 23 : J. Hypertension, 1996 Feb. 14(2) : 223-8. 
40. Predictors of cardiovascular and all-cause mortality, especially 
among hypertensive subjects; five year follow-up of Hoorn Study. 
Jager A, Kostence P J, Ruke HG, Heine RJ, Nijpels G, Dekker JM, 
Bouter LM, Stehouwer CD.  
41. Viberti G, Martin J, Jose W. Mersent P J in diabetic nephropathy; 
Josslins Diabetes Mellitus New Delhi : B1 Waverly Pvt. Ltd. 13th 
edition 1996; 696-97. 
42. Alzaid AA, Microalbuminuria in NIDDM population : an overview 
in Diabetes Vol. 19, 1996; (1) 79-89. 
43. Bignazzi R, Bianchi S. Nenci R, Baldari D, Compere VM : 
Increased thickness of the carotid artery in patients with essential 
hypertension and microalbuminuria.  
44. Pontremolli R, Viazzi F, Ruello N, Deferrari G, Microalbuminuria 
– a marker of cardiovascular and organ damage. Kidney Int. Suppl. 
1998 Dec; 63 : 163-5. 
45. Conquering the epidemic of coronary artery disease among Indians 
: crucial role of cardiologists : Enas A Enas, A Senthil Kumar. 
Quarterly Journal of Cardiology : 2002:1. 
46. Will there be an epidemic of cardiovascular diseases in the 
developing countries? K. Srinath Reddy. Quarterly Journal of 
Cardiology : 2002:1. 
47. Evidence of impaired glomerular charge selectivity in nondiabetic 
subjects with microalbuminuria: relevance to cardiovascular 
disease.  
Kofoed –Enevoldsen A, Foyle WJ, Fernandez M, Yudkin JS. 
Arterioscler Thromb Vasc Biol, 1996 Mar, 16(3) : 450-4. 
Steno Diabetes Centre, Gentofte, Denmark. 
48. Association of microalbuminuria and atherosclerotic risk factors in 
non-diabetic subjects in Korea. 
Kim CH, Kim, Park JY, Park HS, Hong SK, Park SW, Lee KU. 
Diabetes Res Clin. Pract. 1998 Jun: 40(3) : 191-9. 
49. Atherosclerotic risk factors are increased in clinically healthy 
subjects with microalbuminuria. JensenJ S, Borch-Johnsen K, 
Jensen G, Feldt-Rasmussen B. Atherosclerosis, 1995 Jan. 20; 
112(2) : 245-52. 
50. Microalbuminuria and markers of the atherosclerotic process : te 
D.E.S.I.R. Study.  
Mennen LI, Blakau B, Royer B, Caradec A, Marre M, Balkau B, E, 
Althen Gelas F, Bechetoille A, GalloisY, GIrault A, Marre M. 
Chesnier MC.  
51. Microalbuminuria reflects as generalized transvascular albumin 
leakiness in clinically healthy subjects. 
     Jensen JS, Borch-Johnsen K, Jensen G, Feldi-Rasmussen B. 
52. The importance of microalbuminuria as a cardiovascular risk 
indicator : A review.  
Diercks GF, van Boven AJ, Hillege JL, de Jong PE, Rouleau JL, 
van Gilst WH. Can J Cardiol, 2002 May; 18(5) : 525-35. 
53. Microalbuminuria : marker of vascular dysfunction, risk factor for 
cardiovascular disease. Garg JP, Bakris GL. Vasc Med. 2002 Feb; 
7(1) : 35-43. 
54. Non-diabetic microalbuminuria, endothelial dysfunction and 
cardiovascular disease.  Pedrinelli R, Dell’ Omo G, Penno G, 
Mariani M. Vasc Med. 2001 Nov. 6(4) : 257-64. 
55. Urinary albumin excretion in hospitalized patients with acute 
myocardial infarction. Prevalence of microalbuminuria and 
correlation to left ventricle wall thickness. Taskiran M, Feldt-
Rasmussen B, Jensen GB, Jensen JS. Scand Cardiovasc J. 1998; 
32(3) : 163-6. 
56. Microalbuminuria in nondiabetic adults; relation of blood pressure, 
body mass index, plasma cholesterol levels, and smoking : The 
Gubbio Population Study. Cirillo M, Seningalliesi L, Laurenzi M, 
Alfieri R, Stamler J. Stamler R, Panarelli W, De Santo NG. Arch 
Intern Med. 1998 Sep. 2 
57. Microalbuminuria is common, also in a nondiabetic, 
nonhypertensive population, and an independent indicator of 
cardiovascular risk factors and cardiovascular morbidity. 
Hillege HL, JansseN WM, Bak AA, Diercks FG, Grobee DE, 
Crijns JH, Van Gilst WH, de Zeeuw D, De Jong PE; The Prevent 
Study Group. J Intern Med. 2001 Jun; 249(6 ) : 519-26. 
58. Microalbuminuria as predictor of vascular disease in non-diabetic 
subjects. Islington Diabetes Survey. Yudkin JS, Forrest RD, 
Jackson CA. Lancet, 1988 Sep. 3 : 2 (8610) : 530-3. 
59. Serum homocysteine level and protein intake are related to risk of 
microalbuminuria : the Hoorn Study.  
Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter 
LM, Donker AJ, Stehouwer CD. Kidney Int. 1998 Jul 54(1) : 203-
9. 
PROFORMA 
Case Number 
Name     Age/Sex 
Ward/Bed     
Date of Admission 
Address 
Presenting complaints  
History of Presenting complaints 
Past History 
1. History of angina 
If yes NYHA grade. 
2. History of previous Myocardial infarction  
If yes when 
3. History of Hypertension  
4. History of claudications 
5. History of stroke 
6. History of any renal disease 
Drug History 
Personal History  
 Smoking  Tobacco  Cigarette  Beedi 
 Alcoholism 
 Any other addiction 
 Diet 
 Bowel/Bladder/Sleep/Appetite 
 Obstetric and Menstural History 
 Socio-economic history 
   Level of education 
   Occupation 
   Family structure 
 Physical Examination  
 General examination 
  Built & Nourishment 
  Consciousness & Orientation 
  Height Weight 
  Pallor   Icterus Cyanosis 
  Clubbing  Oedema  Lymphnodes 
  JVP   Temp.  Pulse 
  B.P.   R.R. 
SYSTEMIC EXAMINATION 
1. Cardiovascular System 
 Inspection  - Precordium 
- Apex beat 
- Visible Pulsation 
Palpation  - Apex beat 
- Parasternal impulse 
- Thrills 
Percussion  - 
Auscultation S1  S2  S3  S4 
    Advertitious sounds 
    Murmur 
2. Reparatory system 
3. Per abdomen  
4. CNS 
INVESTIGATIONS 
1. Complete Blood Picture - H  TLC DLC ESR 
     - TRBC Platelet count 
2. Blood sugar   - Fasting 
     - Post meal 
3. Blood urea 
4. Serum creatinine 
5. Serum uric acid 
6. Serum total cholesterol 
7. Microalbuminuria 
8. Urine-Sugar  Albumin Ketone Microscopy  
9. X-ray chest PA view 
10. ECG 
11. Echo 
ABBREVIATIONS 
Apo-A  Apolipoprotein –A  
BP   Blood Pressure 
BMI   Body Mass Index 
CAD   Coronary Artery Disease 
CHD   Coronary Heart Disease 
CRP   C-Reactive Protein 
DM   Diabetes Mellitus 
DAM   Di acetyl monoxime 
EF   Ejection Fraction 
F   Female 
GOD   Glucose Oxidase 
Hb   Hemoglobin 
HDL   High Density Lipoprotein 
HTN   Hypertension 
Ht   Height 
IDDM  Insulin Dependant Diabetes Mellitus 
IgG   Immunoglobulin G 
IHD   Ischemic Heart Disease  
IPD   In Patient Department 
IRAS   Insulin REsistance Atherosclerosis Study 
LVH   Left Ventricular Hypertrophy 
M   Male 
MAL   Microalbuminuria 
MAU   Microalbuminuria 
NIDDM  Non Insulin Dependant Diabetes Mellitus 
OPD   Out Patient Department 
PAD   Peripheral Artery Disease 
POD   Peroxidase 
PR   Pulse Rate 
R/M   Routine / Microscopy  
Tch   Total Cholesterol 
WHO   World Health Organization 
Wt   Weight 
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No. Age Sex Pulse Bp(mmHg) B.M.L Diagnosis smoking Total Cholestrol Microalbuminuria ECG Changes
1 30 M 84/min 110/70 25.8 ASMI  - ve 203  + ve q V1-V6, ST ↑ V1-V6 T ↓
2 32 M 78/min 120/74 26.04 ASMI + 183  - ve ST ↑ T ↑ V1-V6, reciprocal in II, III avF
3 35 M 66/min 100/68 21.48 ASMI  - ve 211  - ve q V1-V6, ST↑ V1-V6 T ↓
4 35 M 88/min 120/80 25.9 ASMI  - ve 188  - ve ST ↑ T ↑ V1-V6
5 35 M 77/min 84 systolic 20.1 ASMI + 206  - ve q V1-V4, ST ↑
6 37 M 86/min 114/74 19.53 ASMI + 130  + ve ST ↑T↑ V1-V6 , reciprocal in II,III avF
7 39 M 74/min 124/80 25.28 ASMI + 160  + ve ST ↑ T ↑ V1-V6
8 40 M 68/min 106/76 25.95 ASMI + 234  + ve q V1-V6, ST ↑ V1-V6 T ↓
9 40 M 82/min 96 systolic 26.29 ASMI + 170  + ve q V1-V6, ST ↑ V1-V6 T ↓
10 41 M 54/min 90/70 26.44 IWMI + 213  - ve ST ↑ II, III avF T↑
11 42 M 68/min 84/60 26.56 ASMI  - ve 150  + ve q V1-V6, ST↑ V1-V6 T ↓
12 42 M 56/min 80 systolic 26.39 AWMI with IWMI + 232  + ve q V1-V6, ST ↑ II, III avF
13 43 M 48/min 120/70 23.87 IWMI + 207.4  + ve ST ↑ II, III avF 
14 45 M 82/min 130/84 27.54 ASMI + 160  + ve ST ↑ T ↑ V1-V6
15 45 M 75/min 116/76 26.29 ASMI + 211  + ve q V1-V6, ST↑ V1-V6 T ↓
16 46 M 71/min 110/70 24.91 ASMI + 225  + ve q V1-V6, ST↑ V1-V6 T ↓
17 48 M 68/min 90/70 24.5 IWMI + 185  + ve ST ↑ II, III avF
18 48 M 52/min 100/70 27.2 IWMI + 157  + ve ST ↑ II, III avF T↑
19 50 M 68/min 120/82 23 AWMI + 206.2  + ve q V1-V6, ST↑ V1-V6 T ↓
20 50 M 74/min 90 systolic 26.5 IWMI with PWMI + 203  + ve ST ↑ II, III avF T↑ V1
21 50 M 52/min 100/70 23.5 IWMI with PWMI + 156.7  + ve ST ↑ II, III avF T↑ V1
22 50 M 54/min 120/64 21 IWMI + 163  + ve ST ↑ II, III avF
23 52 M 60/min 114/74 28.4 IWMI + 201  + ve ST ↑ II, III avF T↑
24 54 M 70/min 134/84 21.5 ASMI  - ve 203  + ve q V1-V6, ST↑ V1-V6 T ↓
25 55 M 74/min 116/66 22.5 ASMI + 206  + ve q V1-V6, ST↑ V1-V6 T ↓
26 55 M 72/min 96/70 22.3 IWMI with PWMI + 184  + ve ST ↑ II, III avF T↑ V1
27 58 M 74/min 100/80 26.8 ASMI + 134  + ve q V1-V6, ST↑ V1-V6 T ↓
28 58 M 76/min 104/68 25.6 OLD AWMI with 
IWMI
+ 216  + ve q V1-V6, ST ↑ II, III avF
29 58 M 58/min 110/70 23.8 I I + 245  + ve ST ↑ II, III avF
30 60 F 56/min 120/74 27.4 IWMI + 165  - ve ST ↑ II, III avF
31 40 F 68/min 124/80 22 ASMI  - ve 135 NEG q V1-V6, ST↑ V1-V6 T ↓
32 43 F 72/min 80 systolic 23 RVMI  - ve 194 NEG ST ↑ V1, V4R
33 45 F 74/min 120/68 26 ASMI  - ve 195 NEG q V1-V6, ST↑ V1-V6 T ↓
34 48 F 76/min 110/74 20.4 ASMI  - ve 138 NEG ST ↑ T ↑ V1-V6, reciprocal in II, III avF
35 50 F 82/min 120/80 19.6 IWMI  - ve 184 NEG ST ↑ II, III avF T↑
36 50 F 84/min 126/76 20.3 AWMI  - ve 137 NEG q V1-V6, ST↑ V1-V6 T ↓
37 50 F 86/min 112/72 26.3 AWMI  - ve 228.8  + ve q V1-V6, ST↑ V1-V6 T ↓
38 55 F 62/min 96/64 21 IWMI  - ve 148.5 NEG ST ↑ II, III avF T↑
39 55 F 64/min 120/74 25.1 ASMI  - ve 212.6  + ve q V1-V6, ST↑ V1-V6 T ↓
40 55 F 74/min 100/64 20.4 ASMI  - ve 205 NEG ST ↑ T ↑ V1-V6, reciprocal in II, III avF
41 55 F 82/min 120/80 25.2 IWMI  - ve 183 NEG ST ↑ II, III avF T↑
42 55 F 86/min 110/86 20.6 ASMI  - ve 205  + ve q V1-V6, ST↑ V1-V6 T ↓
43 55 F 72/min 74 systolic 25.8 RVMI WITH IWMI  - ve 208  + ve ST ↑ II, III avF T↑ ST↑ V1, V4R
44 55 F 74/min 120/80 25.1 ASMI  - ve 216  + ve q V1-V6, ST↑ V1-V6 T ↓
45 55 F 68/min 110/70 19.6 ASMI  - ve 165 NEG q V1-V6, ST↑ V1-V6 T ↓
46 55 F 58/min 114/72 25.6 IWMI  - ve 200.8  + ve ST ↑ II, III avF T↑
47 60 F 82/min 116/66 20.3 ASMI  - ve 168 NEG ST ↑ T ↑ V1-V6, reciprocal in II, III avF
48 60 F 48/min 120/84 25.4 IWMI with heartblock  - ve 204  + ve ST ↑ II, III avF T↑, Heart Block
49 60 F 68/min 100/70 24.2 ASMI  - ve 176 NEG ST ↑ T ↑ V1-V6
50 60 F 74/min 110/68 26.5 IWMI  - ve 215  + ve ST ↑ II, III avF
ECHO
Akinetic AW & septum EF 74.8%
Akinetic AW & septum EF 65 % Apical aneurysm
Akinetic AW & septum EF 43.63 %
Akinetic AW & septum EF 58 %
Hypokinetic AW & septum poor LV function
Akinetic AW & septum EF 65.6 %
Akinetic AW, apex & septum EF 65.6 %
Hypokinetic AW & septum EF 65 %
Hypokinetic Iw
Akinetic AW & septum EF 43.63 %
Akinetic AW, IW & septum EF 40 %
Hypokinetic IW EF 53 %
Akinetic AW & septum EF 52 %
Akinetic AW & septum EF 50 %
Hypkinetic IW EF 60.9%
Hypokinetic IW EF 38.6 %
Akinetic AW & Septum EF 46 %
Hypokinetic IW, PW, EF 41 %
Hypokinetic IW, PW
Hypokinetic IW, EF 39.7 %
Hypokinetic IW EF 72.8 %
Akinetic AW & septum EF 62 %
Akinetic AW & septum
Hypokinetic IW , PW
Hypokinetic AW & septum EF 44 %
Akinetic AW & septum EF 40 %
Hypokinetic IW, aortic dilatation EF 42.8 %
Hypokinetic IW EF 65 %
Akinetic AW & septum EF 58 % 
Hypokinetic RV, EF 40 %
Akinetic AW & septum EF 74.68 %
Akinetic AW & septum EF 62 %
Hypokinetic IW EF 68.3 %
Akinetic AW & septum EF 54 %
Akinetic AW & septum EF 88.9%
Akinetic AW & septum EF 61.4 %
Hypokinetic IW  EF 52 %
Akinetic AW & septum EF 58 % diastolic dysfunction
Hypokinetic AW & septum poor LV function EF 43 %
Akinetic AW & septum EF 59.2 %
Hypokinetic IW EF 53.8 %
MASTER CHART CASES
Akinetic AW & septum, poor LV compliance
Hypokinetic IW EF 54 % MR likely
Hypokinetic AW & septum poor LV function EF 38 %
Hypokinetic IW EF 54 %
Hypokinetic IW EF 56.5%
Akinetic AW & septum EF 63.5 %
Hypokinetic IW , RV 44 %
No Age Sex Pulse BP(mmHg) B.M.I Total Cholestrol Smoking Microalbuminuria ECG changes
1 30 M 74/min 100/84 22 165  +ve Neg Normal
2 32 M 82/min 114/76 20 173   -ve Neg Normal
3 35 M 84/min 118/72 25.8 184  +ve Neg Normal
4 35 M 66/min 110/78 21 168  +ve Neg Normal
5 35 M 72/min 120/82 19 138   -ve Neg Normal
6 37 M 75/min 114/78 23 179   -ve Neg Normal
7 39 M 68/min 116/80 22 156  +ve Neg Normal
8 40 M 65/min 114/76 24 176  +ve Neg Normal
9 40 M 74/min 110/72 26.3 173   -ve Neg Normal
10 41 M 82/min 116/86 23 191   -ve Neg Normal
11 42 M 94/min 114/72 25.4 214  +ve Neg Normal
12 42 M 88/min 112/86 20 164   -ve Neg Normal
13 43 M 84/min 112/82 24 193  +ve Neg Normal
14 45 M 78/min 116/76 23 176   -ve Neg Normal
15 45 M 85/min 120/78 27 185   -ve Neg Normal
16 46 M 73/min 116/72 22 178  +ve Neg Normal
17 48 M 68/min 118/84 20 168   -ve Neg Normal
18 48 M 75/min 110/72 24 212  +ve Neg Normal
19 50 M 65/min 114/74 23 184  +ve Neg Normal
20 50 M 60/min 110/86 24.16 175  +ve  + ve Normal
21 50 M 74/min 116/76 27 203  +ve  + ve Normal
22 50 M 82/min 112/82 22 165   -ve Neg Normal
23 52 M 71/min 110/74 25.5 168  +ve  + ve Normal
24 54 M 68/min 100/82 26 176  +ve  + ve Normal
25 55 M 76/min 116/76 24 153   -ve Neg Normal
26 55 M 77/min 118/72 21 209  +ve  + ve Normal
27 58 M 84/min 100/86 20 204   -ve Neg Normal
28 58 M 90/min 118/76 26.3 178  +ve  + ve Normal
29 58 M 65/min 100/76 24 194  +ve  + ve Normal
30 60 M 68/min 114/86 22 187  +ve  + ve Normal
31 40 F 73/min 116/86 20 176   -ve Neg Normal
32 43 F 78/min 100/76 21 164   -ve Neg Normal
33 45 F 84/min 116/72 20 156   -ve Neg Normal
34 48 F 81/min 114/86 23 154   -ve Neg Normal
35 50 F 80/min 100/78 22 183   -ve Neg Normal
36 50 F 78/min 118/74 20 175   -ve Neg Normal
37 50 F 74/min 116/76 19 167   -ve Neg Normal
38 55 F 68/min 100/84 20 154   -ve Neg Normal
39 55 F 75/min 112/86 23 148   -ve Neg Normal
40 55 F 68/min 116/76 22 152   -ve Neg Normal
41 55 F 82/min 100/82 21 162   -ve Neg Normal
42 55 F 76/min 100/70 20 174   -ve Neg Normal
43 55 F 85/min 112/80 21 177   -ve Neg Normal
44 55 F 88/min 116/70 25.45 183   -ve Neg Normal
45 55 F 90/min 118/84 21 158   -ve Neg Normal
46 55 F 68/min 100/70 20 146   -ve Neg Normal
47 60 F 75/min 120/80 26 152   -ve  + ve Normal
48 60 F 76/min 116/72 25 157   -ve  + ve Normal
49 60 F 84/min 100/70 21 206   -ve Neg Normal
50 60 F 80/min 118/82 19 182   -ve Neg Normal
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